FierceBiotech15h
Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
BioPharma Dive6h
Dietmar Berger is Gilead’s new CMO; Padlock investors sue Bristol Myers
Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...
ENDPOINTS NEWS12h
Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set
Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...
The Pharma Letter12h
Gilead Sciences names new CMO
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
GlobalData on MSN4d
Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...
pharmaphorum5y
Sanofi names ex-Roche cancer guru Dietmar Berger as development lead
Roche alumnus Dietmar Berger has joined Sanofi as head of development following a short stint in biotech. In his new role Berger will oversee the company’s clinical portfolio across all ...